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Summary
Background Psoriasis is associated with several comorbidities and behavioural risk
factors.
Objectives To evaluate demographic and disease characteristics in patients enrolled
in the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
Methods PSOLAR is a global, prospective, longitudinal, disease-based registry that
includes a postmarketing commitment to evaluate safety in patients with psoria-
sis. Enrolled patients had to be receiving, or be eligible to receive, conventional
systemic or biological agents. Demographic/disease characteristics, medical histo-
ries, lifestyle risk factors and previous treatments are collected at enrolment. Efﬁ-
cacy and safety data are collected every 6 months for 8 years, and data are
extracted annually. Selected parameters are evaluated by age quartile using post
hoc analyses.
Results As of 23 August 2012, 11 900 patients were enrolled at 301 sites in North
America, Europe and Latin America. Over half of the PSOLAR population (547%)
is male, with a mean age of 486 years and mean body mass index of
309k gm
2 at enrolment. Mean duration of disease at enrolment was 175 years,
and mean Physician’s Global Assessment score was 20. Psoriatic arthritis (355%)
and cardiovascular diseases (382%) were highly prevalent. Diabetes mellitus type
II was reported in 114% of patients. Depression and anxiety were noted in 147%
and 111% of patients, respectively; 790% reported any alcohol use and 567%
reported smoking or a history of smoking. The occurrence of most comorbidities,
including cardiovascular disease and risk factors, increased with age.
Conclusions In the PSOLAR population, multiple and age-appropriate comorbidities
are associated with psoriasis and may affect the selection of psoriasis treatments.
What’s already known about this topic?
￿ Psoriasis is a complicated disorder, often accompanied by multiple comorbidities.
￿ Demographic and disease characteristics of patients with psoriasis reported from
large claims datasets may be affected by misclassiﬁcation bias or coding errors.
￿ In clinical trials, many patients are excluded owing to strict inclusion criteria.
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￿ Data collected by the Psoriasis Longitudinal Assessment and Registry reveal that the
demographics and disease characteristics of patients with psoriasis who are receiv-
ing, or are candidates for, systemic therapy in actual clinical care resemble those
reported in clinical trials.
￿ Most comorbidities occur more frequently in older patients, who, in turn, may
require more comprehensive overall medical care.
Psoriasis is a common, chronic, inﬂammatory, immune-medi-
ated disease that manifests with scaly, erythematous plaques on
the skin.
1 Psoriatic disease is often associated with a variety of
comorbid conditions, including psoriatic arthritis (PsA), which
has been estimated to occur in one-third of patients with psori-
asis.
2 Likewise, cardiovascular conditions and risk factors,
including diabetes, hypertension, hyperlipidaemia, obesity and
metabolic syndrome, as well as chronic pulmonary disease and
Crohn disease, are commonly reported among patients with
psoriasis.
3–10 Patients with psoriasis have an increased risk of
depression and anxiety compared with the general popula-
tion,
11 and lifestyle risk factors that may exacerbate psoriasis
itself or complications of the disease, such as smoking and alco-
hol use, are highly prevalent in this patient population.
12
Current understanding of the typical proﬁle of a patient
with psoriasis, including demographic and disease characteris-
tics, as well as common comorbidities and standard-of-care
treatment, is based mainly on large datasets derived from
claims databases or populations enrolled in clinical trials.
However, such studies have limitations, including coding
accuracy and criteria required for enrolment, respectively.
13
Although patient registries may also have limitations, such as
participation, recall and other forms of bias, such observa-
tional studies allow for the collection of valuable data during
continuous treatment in actual practice settings.
14,15
The Psoriasis Longitudinal Assessment and Registry (PSOLAR)
is a large, international, longitudinal, disease-based registry with
prospective enrolment of patients with psoriasis who are receiv-
ing, or are candidates for treatment with, systemic therapies.
16
This observational study, which supports a postmarketing com-
mitment of the sponsor (Janssen Scientiﬁc Affairs, LLC, Horsham,
PA, U.S.A.), provides the opportunity to collect epidemiological
data on patients with psoriasis who are treated in real-life derma-
tological practices primarily in North America and Europe. This
report provides a comprehensive description of demographics,
disease characteristics, medical history, lifestyle risk factors (i.e.
alcohol use and smoking) and treatments prior to enrolment in
PSOLAR. These data are further analysed to determine how the
prevalence of certain comorbidities and social behaviours com-
monly observed in patients with psoriasis may vary with age.
Methods
PSOLAR is a prospective, 8-year, longitudinal, disease-based
registry designed to collect safety, clinical outcome, quality of
life and comorbidity data from patients with psoriasis who are
receiving, or are eligible to receive, conventional systemic or
biological therapies. PSOLAR patients are enrolled at nearly
300 academic, community-based and hospital-afﬁliated clinical
practices in 16 countries.
16 To meet the need for postmarket-
ing surveillance of the long-term safety of psoriasis therapies
developed by the sponsor within the registry population,
enrolment was planned for approximately 12 000 patients and
to accommodate patients exposed to not only sponsor-pro-
duced biologics (i.e. ustekinumab and inﬂiximab), but also
other biological agents (e.g. adalimimumab and etanercept),
as well as other nonbiological therapies (e.g. immunomodula-
tors and/or phototherapy).
The design and utility of PSOLAR, as well as the role of the
chartered Steering Committee (see Appendix 2), have been
reported previously.
16 PSOLAR was conducted in accordance
with guidelines from the Agency for Healthcare Research and
Quality.
17 Brieﬂy, eligible patients (aged ≥ 18 years) must
have had a diagnosis of moderate-to-severe plaque or other
form of psoriasis for which they were receiving, or were candi-
dates for receiving, treatment with systemic therapies. As with
all observational studies, study physicians prescribe treatment
based solely on the usual practices of care. The registry does
not allocate patients to speciﬁc treatment or restrict the use of
commercially available medications as monotherapy or in com-
bination. Sites collect a core set of data that includes demo-
graphics, disease activity, medical history and previous
medications at enrolment; safety data are collected at each study
visit every 6 months for a minimum of 8 years.
Speciﬁed data are collected by site personnel using the fol-
lowing methods: (i) direct contact (i.e. ofﬁce visit or, in lim-
ited circumstances, by telephone) with the patient; (ii) review
of the patient’s medical records; or (iii) contact with the
patient’s primary care physician or specialty physician
involved in the patient’s medical care. Data collected at each
site include demographic and disease characteristics, medical
histories, lifestyle risk factors, and previous medication expo-
sure using electronic case report forms, which were designed
to query for speciﬁc parameters and offered the option to pro-
vide additional information for certain queries. For example,
patients were queried for the presence of PsA and, if present,
they were asked if the diagnosis of PsA had been conﬁrmed
by a joint specialist.
For this report, epidemiological data (i.e. demographic and
disease characteristics, individual and family medical history,
© 2014 The Authors. British Journal of Dermatology
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ment, as well as history of infection requiring prescription
treatment in the 3 years prior to enrolment, were summarized
using descriptive statistics. Selected parameters [i.e. body mass
index (BMI), medical history and social activity] were summa-
rized by age quartiles of 18–35 years (Q1), 36–50 years
(Q2), 51–65 years (Q3) and > 65 years (Q4). This report
includes data for patients enrolled prior to the annual database
extract on 23 August 2012.
Results
As of the 23 August 2012 PSOLAR data extract, 11 900 of the
12 000 targeted patients were enrolled at 301 global sites in
North America, Europe and Latin America. The ﬁrst patient
was enrolled on 20 June 2007. More than 90% of sites are
located in North America (i.e. approximately 750% in the
U.S.A. and approximately 160% in Canada) (Fig. 1).
At enrolment, the mean patient age was 486 years and the
mean BMI was 309k gm
2 (Table 1). Just over half of the
PSOLAR population at this time were men (547%), with
the majority being white (831%). Approximately 800% of
patients in PSOLAR were either overweight or obese at enrol-
ment. Based on the National Heart, Lung, and Blood Institute
Obesity Education Initiative criteria, nearly half of the patients
were obese at enrolment: 243% were of class I obesity status
(BMI 300–349), 131% were of class II obesity status (BMI
350–399) and 108% were of class III obesity status
(BMI ≥ 40); an additional 321% of patients were overweight.
Disease characteristics
The mean percentage of body surface area (BSA) affected by
psoriasis was 121% at enrolment, which is signiﬁcantly lower
than the mean BSA affected at peak historical disease activity
(297%) (Table 2). This ﬁnding is consistent with the fact that
many patients were receiving treatment for psoriasis at the
time of registry enrolment. Similarly, the mean Physician’s
Global Assessment (PGA) score was 20 at entry compared
with 31 at peak activity. Approximately three quarters of
patients had a mean PGA score indicative of minimal (1), mild
(2) or moderate (3) psoriasis at enrolment (232%, 281% and
275%, respectively), whereas almost all patients had moderate
(464%), marked (264%) or severe (70%) psoriasis at peak
disease activity. Overall, 969% of patients enrolled in PSOLAR
had plaque psoriasis (Table 1). The mean time since psoriasis
had been diagnosed was 175 years, and the mean time since
the highest degree of disease activity was 33 years.
Comorbidities and family history
Approximately one-third of patients (355%; n = 4226)
reported a history of PsA at the time of enrolment in PSOLAR
(Table 3), with 1664 patients (141%) having their diagnosis
conﬁrmed by a joint specialist. A family history of psoriasis
was reported by 455% of patients, while 103% noted a fam-
ily history of PsA (Table 4). There was a high proportion of
patients (382%) with a history of cardiovascular disease [e.g.
myocardial infarction (24%), transient ischaemic attack or
stroke (12%), and congestive heart failure (10%)] and risk
factors [e.g. hypertension (297%), hyperlipidaemia (186%)
and diabetes mellitus type II (114%)] (Table 3), with a fam-
ily history of cardiovascular disease reported by 447% of
patients (Table 4).
A history of pulmonary conditions was reported for 144%
of patients [e.g. asthma (80%) and sleep apnoea (57%)],
while a history of hepatic conditions [e.g. cirrhosis (08%),
hepatitis B (05%) and hepatitis C (11%)] was noted in
< 50% of patients (Table 3). Liver biopsies had been per-
USA (74·9%)
Canada (15·7%)
EU/ME (8·5%)
LatAm (<1·0%)
EU/ME = Europe (Austria, Belgium, Czech Republic, Greece, Netherlands, 
LatAm = Latin America (Argentina, Chile, Colombia, Mexico)
  Portugal, Slovakia, Slovenia, Ukraine) and Middle East (Israel)
Fig 1. Proportion of patients enrolled in the Psoriasis Longitudinal
Assessment and Registry by country.
Table 1 Demographic and disease characteristics at enrolment
(enrolled patients)
Patients enrolled n = 11 900
Sex, male 6513 (547)
Race, white 9890/11 898 (831)
Age (years) 486  139
BMI (kg m
2)3 0 9  72
BMI category
a 11 703
Underweight (BMI < 185) 59 (05)
Normal (BMI 185–249) 2235 (191)
Overweight (BMI 250–299) 3762 (321)
Obesity class I (BMI 300–349) 2845 (243)
Obesity class II (BMI 350–399) 1537 (131)
Obesity class III (BMI ≥400) 1265 (108)
Psoriasis type 11 854
Plaque 11 491 (969)
Other 1089 (92)
Duration of psoriasis (years) 11 777
Mean  SD 175  135
Values are n (%) of patients or mean  SD. BMI, body mass
index.
aObesity class based upon National Heart, Lung, and
Blood Institute Obesity Education Initiative (http://www.nhlbi.
nih.gov/about/oei/).
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patients (n = 31) had a history of alcoholic liver disease. A
history of ulcerative colitis (08%) or Crohn disease (05%)
was rarely noted. Similarly, low proportions of patients with
neurological conditions, including demyelinating disease
(02%) and multiple sclerosis (01%), and other autoimmune
conditions, such as lupus (03%), were observed.
Overall, 246% of patients reported signiﬁcant infections
requiring prescription medication within the 3-year interval
before enrolment. Most prior infections were bacterial in nat-
ure (216%); opportunistic infections (as deﬁned by the site
investigator) were uncommon (12%). A history of basal cell
(BCC) and squamous cell carcinoma (SCC) was reported for
38% and 24% of patients, respectively, and a history of other
cancers was reported in 37% of patients (Table 3), including
lymphoma (n = 14) in approximately 01% of patients. A his-
tory of psychiatric disease was noted in 207% of patients.
Among the psychiatric conditions commonly associated with
psoriasis, depression was reported for 147% of patients and
anxiety for 111% (Table 3). High proportions of patients
reported current or previous alcohol use of any kind (790%),
or smoking in any capacity (567%) (Table 5).
Previous treatment
At enrolment, 973% of patients had been treated with topical
therapy, 546% with phototherapy and 436% with retinoids,
such as acitretin (199%), and 476% with immunomodula-
tors, such as methotrexate (406%) and ciclosporin (156%)
(Table 6). Nearly three-quarters (721%) had received biolog-
ical therapy prior to entry into the registry: 390% had
received one biological agent and 293% had received two or
three biological agents. Speciﬁc biological agents received by
patients enrolled in PSOLAR prior to enrolment included eta-
nercept (405%), adalimumab (294%), ustekinumab
(187%), inﬂiximab (152%), efalizumab (112%), alefacept
(58%) and/or others (23%).
Baseline characteristics by age quartile
Selected baseline characteristics were analysed by age quartiles
of 18–35 years (Q1), 36–50 years (Q2), 51–65 years (Q3)
and > 65 years (Q4). Mean BMI values were comparable in
the Q1 (295), Q2 (314), Q3 (315) and Q4 (301) groups
(Table 7). The proportions of patients with class I obesity sta-
tus increased consistently with age, but only by a few percent-
age points, while the Q1 (youngest) and Q4 (oldest) groups
had similar and slightly lower proportions of patients with
class II/III obesity status.
The proportion of patients that reported PsA was lowest in
the Q1 group (236%), and comparably higher among the Q2
(372%), Q3 (407%) and Q4 (350%) groups (Table 8). The
proportion with a history of cardiovascular disease and risk
factors generally increased with age. The same trend was
observed for most other medical history categories and indi-
vidual diseases. Of note, the proportion of patients with dia-
betes mellitus II was noticeably lower for the Q1 (23%) and
Q2 (71%) age groups compared with the Q3 (175%) and
Q4 (212%) age groups, as were those with hypertension and
hyperlipidaemia.
Finally, the proportions of patients with a history of overall
psychiatric disease increased slightly with age across the Q1,
Q2 and Q3 groups; a similar pattern was observed for history
of depression (Table 9). In contrast, generally similar propor-
tions of patients with a history of anxiety, bipolar disorder
and suicidal ideation were observed across age groups. The
proportions of patients reporting current use of alcohol or
identiﬁed as current smokers generally decreased with age,
while the proportions of those who had stopped using alcohol
or smoking consistently increased with age (Table 9).
Discussion
PSOLAR, which began in 2007, is a prospective, longitudinal,
disease cohort study for patients with psoriasis who are eligi-
All patients
Patients with peak historic data
Enrolment
a Peak historic
BSA by palm method 11 756 6746 6772
Mean  SD 121  1751 3 6  1904 297  248
PGA score 11 360 6606 6845
Mean  SD 20  122 0  122 31  10
PGA score distribution 11 360 6606 6845
0 = clear 1335 (118) 767 (116) 171 (25)
1 = minimal 2633 (232) 1544 (234) 258 (38)
2 = mild 3196 (281) 1782 (270) 959 (140)
3 = moderate 3125 (275) 1835 (278) 3174 (464)
4 = marked 873 (77) 548 (83) 1807 (264)
5 = severe 198 (17) 130 (20) 476 (70)
Values are n (%) of patients or mean  SD. BSA, body surface area affected by psoriasis;
PGA, Physician’s Global Assessment.
aIncludes patients for whom data were also collected
for peak disease activity.
Table 2 Disease activity at enrolment and
peak historical level (enrolled patients)
© 2014 The Authors. British Journal of Dermatology
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301 global centres as of the August 2012 database extract,
PSOLAR represents the largest, international, industry-spon-
sored collection of data from a disease-based registry of
patients with psoriasis. As part of postmarketing commitments
to evaluate safety, a primary objective for PSOLAR is to pro-
vide pharmacovigilance reports to regulatory agencies for indi-
vidual sponsor products. However, the registry also provides
data on patients receiving multiple other therapies and offers
relevant information about the disease to the community of
healthcare providers treating patients with psoriasis. Our ﬁnd-
ings conﬁrm that psoriasis is a complex disease frequently
associated with multiple and age-appropriate comorbidities,
which should be considered when evaluating treatment for
psoriasis.
The PSOLAR population represents one with substantial dis-
ease, as indicated by peak historic disease activity (mean PGA
score 31, but mean BSA of 297%) which, on average, pre-
dated enrolment by about 3 years. At entry, patients had
somewhat less severe disease compared with peak historic lev-
els (mean PGA 20, mean BSA 121%), a not unexpected ﬁnd-
ing given that the majority of patients were receiving
treatment for psoriasis at the time of enrolment. The majority
of patients had plaque psoriasis, and nearly half (455%) had
a family history of psoriasis. Overall, 355% reported a history
of PsA at enrolment, consistent with similar populations with
Table 3 Medical history at enrolment (enrolled patients)
Patients enrolled
a n=11 900
Psoriatic arthritis 4226 (355)
Cardiovascular disease 4545 (382)
Hypertension 3527 (297)
Hyperlipidaemia 2215 (186)
Atherosclerotic disease 417 (35)
Coronary artery disease 355 (30)
Myocardial infarction 290 (24)
Angina
b 165 (14)
TIA/stroke 148 (12)
Congestive heart failure 122 (10)
Peripheral arterial disease 68 (06)
Psychiatric disease 2460 (207)
Depression 1751 (147)
Anxiety 1318 (111)
Bipolar 181 (15)
Suicidal ideation 114 (10)
Endocrine disease 2233 (188)
Diabetes mellitus type II 1357 (114)
Thyroid dysfunction 910 (77)
Diabetes mellitus type I 145 (12)
Pulmonary disease 1710 (144)
Asthma 952 (80)
Sleep apnoea 680 (57)
COPD 241 (20)
NMSC
c 657 (55)
Basal cell carcinoma 446 (38)
Squamous cell carcinoma 287 (24)
Melanoma skin cancer 103 (09)
Other types of cancer
d 439 (37)
Hepatic disease 485 (41)
Hepatitis C 129 (11)
Cirrhosis 90 (08)
Drug-induced
e 71 (06)
Hepatitis B 65 (05)
Inﬂammatory bowel disease 273 (23)
Indeterminate colitis 106 (09)
Ulcerative colitis 96 (08)
Crohn disease 58 (05)
Values are n (%) of patients for conditions occurring at an
incidence of at least 05%. TIA, transient ischaemic attack;
COPD, chronic obstructive pulmonary disease; NMSC,
nonmelanoma skin cancer.
aOn the case report form all
patients (n = 11 900) provided a response regarding
psoriatic arthritis status, whereas 11 888 patients reported the
presence of other relevant medical history.
bMay include
noncardiac angina (e.g. bowel angina) if not speciﬁed by
site.
cSome patients had both basal and squamous cell
carcinoma, accounting for the discrepancy between the
total proportion with NMSC and the proportions with
individual types of skin cancer.
dOther types of cancer
were entered manually on the case report form at each
study site. A history of other cancers reported in a
total of ﬁve or more patients included lymphoma
(n = 14), breast (n = 13), gynaecological (n = 10), cervical
(n = 8), colorectal (n = 8), prostate (n = 7), bladder
(n = 6), kidney (n = 6) and sarcoma (n = 6).
eIncludes
drug-induced hepatic disease related to psoriasis or other treat-
ment.
Table 4 Family medical history at enrolment (enrolled patients)
Number of patients with family history data n=11 540
Psoriasis 5246 (455)
Psoriatic arthritis 1193 (103)
Cardiovascular disease 5158 (447)
NMSC 1250 (108)
Melanoma skin cancer 624 (54)
Other cancer 3839 (333)
Diabetes 4450 (386)
Inﬂammatory bowel disease 762 (66)
Indeterminate colitis 200 (17)
Ulcerative colitis 153 (13)
Crohn disease 199 (17)
Sprue/coeliac disease 42 (04)
Values are n (%) of patients. NMSC, nonmelanoma skin cancer.
Table 5 Social activity at enrolment (enrolled patients)
Patients enrolled n=11 900
Alcohol 11 875
Never used 2500 (211)
Current use 7678 (647)
Have used alcohol and stopped 1697 (143)
Smoking 11 882
Never smoked 5139 (433)
Current smoker 2831 (238)
Have smoked and stopped 3912 (329)
Values are n (%) of patients.
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2,18 About 100% reported a fam-
ily history of PsA, although only about 150% of patients had
PsA diagnosed by a joint specialist. PSOLAR includes a broad
spectrum of patients with psoriasis who may or may not be
normally eligible for clinical trials. Many demographic features
of the PSOLAR population reported at enrolment (e.g. age) and
disease characteristics (e.g. % BSA) reported at peak historic
levels are generally similar to those reported in phase III clinical
trials and other observational studies of biologics in psoriasis,
while others (e.g. male : female ratio) may differ.
19–27
Interestingly, the proportion of women enrolled in PSOLAR
and other observational studies of biological agents was 100–
150% higher than that reported in many clinical trials, which
may be because women of childbearing age are less inclined to
participate in studies of experimental agents.
Based upon National Heart, Lung, and Blood Institute Obes-
ity Education Initiative criteria, about 20% of patients were of
normal body weight status at enrolment in PSOLAR, while a
remarkable 80% were overweight or obese. Furthermore, the
rate of obesity at entry into PSOLAR (482%) is higher than
published rates for adults in the U.S.A. and Canada (nearly
250% and 350%, respectively).
28 This is particularly notable
because increased BMI is an established risk factor for cardio-
vascular disease,
29 may impact response to treatment, and
could further burden patients with anxiety, depression and
sleep impairment.
30 Interestingly, the prevalence of weight
problems did not differ much across age quartiles, while the
prevalence of cardiovascular risk factors varied substantially,
suggesting a tendency towards accumulation of these comor-
bidities over time.
There was a high prevalence of cardiovascular disease
(382%) and other cardiovascular risk factors, including
hypertension (297%), hyperlipidaemia (186%) and diabetes
mellitus type II (114%), all of which, along with obesity, are
components of metabolic syndrome. These results are consis-
tent with the reported association between psoriasis and both
cardiovascular risk factors and metabolic syndrome.
31–33 Of
note, the prevalence of cardiovascular risk factors increased
substantially with increasing age, which indicates, as expected,
that cardiovascular comorbidities tend to accumulate over time
in the psoriasis population. Furthermore, high proportions of
patients reported a family history of cardiovascular disease
(447%) and diabetes (386%), likely indicative of a predispo-
sition to such diseases in certain patients with psoriasis.
Some patients reported a history of pulmonary diseases
[e.g. asthma (80%), sleep apnoea (57%) and chronic
Table 6 Previous medication use at enrolment (enrolled patients)
Patients enrolled n=11 900
Number of patients with data available 11 866
Topical therapy 11 542 (973)
Tazarotene 1309 (110)
Calcipotriene/betamethasone 2904 (245)
Topical steroid therapy 11 267 (950)
High potency 9570 (807)
Medium potency 7032 (593)
Low potency 4576 (386)
Phototherapy 6482 (546)
Psoralen plus UVA 2028 (171)
UVB 5438 (458)
Systemic steroids 2782 (234)
Retinoids 5176 (436)
Acitretin 2359 (199)
Immunomodulators 5646 (476)
Ciclosporin 1855 (156)
Methotrexate 4819 (406)
Other immunomodulators 317 (27)
Biological agents(s) 8583 (721)
Inﬂiximab 1808 (152)
Ustekinumab 2220 (187)
Adalimumab 3495 (294)
Alefacept 696 (58)
Efalizumab 1328 (112)
Etanercept 4814 (405)
Other biological agents 277 (23)
Number of biological agents used prior to entry
0 3317 (279)
1 4645 (390)
2–3 3490 (293)
4–7 448 (38)
Values are n (%) of patients for treatments received by at least
20% of patients. UVA, ultraviolet A; UVB, ultraviolet B.
Table 7 Body mass index (BMI) and obesity class by age quartiles (enrolled patients)
Age (years) 18–35 36–50 51–65 > 65
BMI (kg m
2) 2285 4003 4073 1339
Mean  SD 295  758 314  757 315  686 301  617
Obesity class
a 2285 4003 4073 1339
Underweight (BMI < 185) 28 (12) 18 (04) 6 (01) 7 (05)
Normal (BMI 185–249) 682 (298) 685 (171) 622 (153) 246 (184)
Overweight (BMI 250–299) 676 (296) 1293 (323) 1310 (322) 481 (359)
Obesity class I (BMI 300–349) 444 (194) 968 (242) 1071 (263) 361 (270)
Obesity class II (BMI 350–399) 243 (106) 532 (133) 619 (152) 143 (107)
Obesity class III (BMI ≥400) 212 (93) 507 (127) 445 (109) 101 (75)
Values are n (%) of patients, unless otherwise noted, for conditions occurring at a total incidence of at least 05% in any quartile.
aObesity
class based upon National Heart, Lung, and Blood Institute Obesity Education Initiative (http://www.nhlbi.nih.gov/about/oei/).
© 2014 The Authors. British Journal of Dermatology
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While other reports have suggested an association between
COPD and psoriasis, the proportion of patients with a history
of COPD observed in PSOLAR is lower than that reported for
patients with psoriasis elsewhere.
34,35 Generally, COPD occurs
more commonly than asthma, and studies evaluating an asso-
ciation between psoriasis and asthma have been inconclu-
sive.
36 However, in PSOLAR, the higher prevalence of asthma
(80%) compared with COPD is likely attributable to a report-
ing bias due to the overlap of clinical symptoms between
COPD and asthma. The approximately 60% of patients
reporting a history of sleep apnoea is likely related to the high
prevalence of obesity.
As reported elsewhere, there may be an increase in the
background risk of cancer in patients with psoriasis.
36,37
Increased rates of lymphoma have been reported in multiple
cohort studies of patients with psoriasis,
4 and the risk of lym-
phoma with biological agents, in general, remains a topic of
debate.
38 In PSOLAR, about 4% of patients had a history of
some type of cancer other than melanoma and nonmelanoma
Table 8 Medical history by age quartiles
(enrolled patients) Age (years) 18–35 36–50 51–65 > 65
Patients with PsA
data available (n)
2322 4075 4147 1352
Patients with PsA (n) 548 (236) 1517 (372) 1687 (407) 473 (350)
Patients with relevant
medical history data (n)
2321 4068 4144 1352
Cardiovascular disease 223 (96) 1193 (293) 2213 (534) 916 (678)
Hypertension 160 (69) 880 (216) 1747 (422) 740 (547)
Hyperlipidaemia 86 (37) 560 (138) 1109 (268) 460 (340)
Atherosclerotic disease 3 (01) 49 (12) 217 (52) 148 (109)
Peripheral arterial disease 0 7 (02) 36 (09) 25 (18)
Coronary artery disease 3 (01) 40 (10) 183 (44) 129 (95)
Myocardial infarction 2 (01) 46 (11) 137 (33) 105 (78)
Angina
a 3( 0 1) 18 (04) 90 (22) 54 (40)
TIA/stroke 2 (01) 23 (06) 64 (15) 59 (44)
Congestive heart failure 6 (03) 17 (04) 53 (13) 46 (34)
Endocrine disease 135 (58) 535 (132) 1112 (268) 450 (333)
Diabetes mellitus II 54 (23) 290 (71) 726 (175) 286 (212)
Thyroid dysfunction 73 (31) 233 (57) 420 (101) 184 (136)
Diabetes mellitus I 14 (06) 47 (12) 62 (15) 22 (16)
Pulmonary disease 246 (106) 526 (129) 678 (164) 260 (192)
Asthma 207 (89) 302 (74) 318 (77) 125 (92)
Sleep apnoea 39 (17) 225 (55) 325 (78) 91 (67)
COPD 3 (01) 30 (07) 132 (32) 76 (56)
NMSC
b 6( 0 3) 80 (20) 327 (79) 244 (180)
Basal cell carcinoma 5 (02) 60 (15) 227 (55) 154 (114)
Squamous cell carcinoma 1 (< 01) 20 (05) 137 (33) 129 (95)
Other types of cancer
c 13 (06) 60 (15) 204 (49) 162 (120)
Hepatic disease 37 (16) 140 (34) 231 (56) 77 (57)
Hepatitis C 5 (02) 41 (10) 71 (17) 12 (09)
Cirrhosis 5 (02) 20 (05) 48 (12) 17 (13)
Drug-induced
d 9( 0 4) 21 (05) 30 (07) 11 (08)
Hepatitis B 1 (< 01) 26 (06) 30 (07) 8 (06)
Inﬂammatory bowel disease 37 (16) 77 (19) 117 (28) 42 (31)
Crohn disease 17 (07) 22 (05) 18 (04) 1 (01)
Ulcerative colitis 10 (04) 28 (07) 41 (10) 17 (13)
Indeterminate colitis 9 (04) 25 (06) 52 (13) 20 (15)
Values are n (%) of patients, unless otherwise noted, for conditions occurring at a total
incidence of at least 05% in any quartile. PsA, psoriatic arthritis; TIA, transient ischaemic
attack; COPD, chronic obstructive pulmonary disease; NMSC, nonmelanoma skin cancer.
aMay include noncardiac angina (e.g. bowel angina) if not speciﬁed by site.
bSome patients
had both basal and squamous cell carcinoma, accounting for the discrepancy between the
total proportion with NMSC and the proportions with individual types of skin cancer.
cOther types of cancer were entered manually on the case report form at each study site.
A history of other cancers reported in a total of ﬁve or more patients included lymphoma
(n = 14), breast (n = 13), gynaecological (n = 10), cervical (n = 8), colorectal (n = 8),
prostate (n = 7), bladder (n = 6), kidney (n = 6) and sarcoma (n = 6).
dIncludes drug-
induced hepatic disease related to psoriasis or other treatment.
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patients had a family history of such cancers. A history of
NMSC was reported in 55% of patients: 38% with BCC and
24% with SCC, with some patients having had both BCC and
SCC. Although the ratio of BCC to SCC in the general popula-
tion is reported to be 4 : 1
39, exposure to psoralen with ultra-
violet A (170%), as well as immunosuppressive agents, in
some patients in PSOLAR could have increased the risk for
SCC,
40 and a potential reporting bias that could lead to under-
reporting of BCC among dermatologists may have shifted the
expected balance between BCC and SCC.
A history of hepatic disorders was noted in < 5% of patients
enrolled in PSOLAR, although other reports have suggested a
notably higher prevalence of liver diseases, particularly
nonalcoholic fatty liver disease, among patients with
psoriasis.
41,42 The lower prevalence observed in the PSOLAR
population may reﬂect the design of the case report form, which
allows for proactive inquiry about only certain hepatic condi-
tions. Prior liver biopsies were reported in about 20% of
patients. Although the reason for biopsy was not captured, the
majority were presumably performed to monitor for liver
toxicity in patients receiving methotrexate, as per published
guidelines.
43
An increased risk of psoriasis has been reported in patients
with Crohn disease and ulcerative colitis; common inﬂamma-
tory, and even genetic, pathways have been implicated as pos-
sible causes.
44,45 Among patients enrolled in PSOLAR, the
prevalence is 05% for Crohn disease and 08% for ulcerative
colitis. Similar ﬁndings were reported in a large, case–control
study, in which 05% of patients with psoriasis reported a his-
tory of ulcerative colitis at baseline compared with 03% of
age- and sex-matched controls, while the prevalence of Crohn
disease among patients with psoriasis was 05% vs. 02% for
controls.
46
Increased risks of depression, anxiety and suicidality have
been linked to psoriasis.
11,12 In PSOLAR, 147% and 111% of
patients reported a history of depression and anxiety, respec-
tively, which is similar to or lower than the proportions
reported in phase III studies of biological agents.
47–50 How-
ever, the proportion of patients with a history of suicidality in
PSOLAR was lower (10%) than that reported in large surveys
conducted by the National Psoriasis Foundation, which were
conducted before a number of biological agents were
approved for the treatment of psoriasis.
51 Indeed, recent stud-
ies have shown that symptoms of anxiety and depression can
be reduced, although not eliminated, in patients with psoriasis
treated with adalimumab, etanercept, inﬂiximab and us-
tekinumab.
46–49 Additionally, data from PSOLAR support the
literature, which has shown that certain lifestyle behaviours,
such as alcohol use and cigarette smoking, are exhibited more
commonly in patients with psoriasis compared with patients
without psoriasis and that these behaviours may exacerbate
the disease.
4,12,52
A subanalysis of medical history by age quartile showed
that the proportion of patients with certain comorbidities var-
ied with age. As expected, the prevalence of PsA was lowest
among younger patients (aged 18–35 years), given that psori-
asis typically develops 10–12 years before PsA.
2 PSOLAR pro-
vides a long-term opportunity to monitor the incidence of
PsA, as well as the potential impact of therapies on the devel-
opment of PsA, in a large psoriasis population prospectively
over time. Also, as expected, the proportions of patients with
a history of cardiovascular, endocrine, pulmonary and hepatic
diseases, as well as skin cancers and other types of cancer,
generally increased with age. The proportions of patients with
psychiatric illness (e.g. anxiety and depression) were generally
comparable across age quartiles, and the proportions using
alcohol or smoking cigarettes decreased with age. These obser-
vations indicate that, as observed in the general population,
age correlates with the occurrence of various comorbid condi-
tions in patients with psoriasis. Whether the treatment of pso-
riasis with systemic therapies, such as biological agents, may
affect associated comorbidities across age groups remains to
be seen.
In general, observational data are subject to multiple
forms of bias, including treatment selection and outcome
reporting bias. In particular, participation bias on the part of
the prescriber and the patient may exist, as patients who
Age (years) 18–35 36–50 51–65 > 65
Psychiatric disease
a 411 (177) 830 (204) 966 (233) 252 (186)
Depression 269 (116) 588 (145) 716 (173) 177 (131)
Anxiety 252 (109) 450 (111) 487 (118) 129 (95)
Bipolar disorder 40 (17) 69 (17) 62 (15) 10 (07)
Suicidal ideation 20 (09) 44 (11) 41 (10) 9 (07)
Social activity
Alcohol use 2316 4068 4140 1348
Current use of alcohol 1585 (684) 2757 (678) 2608 (630) 726 (539)
Have used alcohol and stopped 237 (102) 543 (133) 669 (162) 248 (184)
Smoking 2320 4069 4142 1348
Current smoker 700 (302) 1113 (274) 862 (208) 156 (116)
Have smoked and stopped 478 (206) 1106 (272) 1651 (399) 677 (502)
Values are n (%) of patients.
aIncludes psychiatric conditions occurring in at least 05% of
patients.
Table 9 Psychiatric disease history and
lifestyle risk factors by age quartiles (enrolled
patients)
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and may be reﬂected in the baseline demographic and com-
orbidity data presented in this report. Additionally, exposure
at baseline may reﬂect prior treatment selection bias. Enrol-
ment in PSOLAR was driven primarily by North American
sites, with > 900% of patients from the U.S.A. and Canada.
Nonetheless, the PSOLAR population provides valuable
insight into the features of a broad group of patients receiv-
ing various treatments for psoriasis in the setting of actual
clinical care.
In summary, PSOLAR is a large (approximately 12 000
patients), prospective, disease-based registry that represents a
valuable resource for collecting information on patient fea-
tures, disease characteristics, previous treatments and comor-
bid conditions to further deﬁne a proﬁle of patients with
psoriasis treated in real-world settings. Additionally, the base-
line demographic features and disease characteristics reported
at peak historic levels in the registry are generally similar to
those reported in clinical trials of biological agents, although
some differences are noted. The data presented here (collected
from 2007 to 2012) further substantiate that psoriasis is asso-
ciated with multiple comorbidities
53 and indicate that patient
age should be considered when evaluating patients with psori-
asis for the presence of certain coexisting conditions. PSOLAR
is an important part of the safety surveillance programme for
ustekinumab and inﬂiximab that is also designed to collect
safety data for other biological agents and systemic therapies.
Consequently, data collected in the PSOLAR registry will be
used to monitor and report long-term safety across a spectrum
of psoriasis therapies.
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